Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Current Opinions and Consensus for Studying Tremor in Animal Models.

Kuo SH, Louis ED, Faust PL, Handforth A, Chang SY, Avlar B, Lang EJ, Pan MK, Miterko LN, Brown AM, Sillitoe RV, Anderson CJ, Pulst SM, Gallagher MJ, Lyman KA, Chetkovich DM, Clark LN, Tio M, Tan EK, Elble RJ.

Cerebellum. 2019 May 23. doi: 10.1007/s12311-019-01037-1. [Epub ahead of print]

PMID:
31124049
2.

Suppression of Harmaline Tremor by Activation of an Extrasynaptic GABAA Receptor: Implications for Essential Tremor.

Handforth A, Kadam PA, Kosoyan HP, Eslami P.

Tremor Other Hyperkinet Mov (N Y). 2018 Jun 26;8:546. doi: 10.7916/D8JW9X9K. eCollection 2018.

3.

Conditions Associated with Essential Tremor in Veterans: A Potential Role for Chronic Stress.

Handforth A, Parker GA.

Tremor Other Hyperkinet Mov (N Y). 2018 May 17;8:517. doi: 10.7916/D8VD8FF5. eCollection 2018.

4.

Linking Essential Tremor to the Cerebellum-Animal Model Evidence.

Handforth A.

Cerebellum. 2016 Jun;15(3):285-98. doi: 10.1007/s12311-015-0750-0. Review.

PMID:
26660708
5.

Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy.

Salanova V, Witt T, Worth R, Henry TR, Gross RE, Nazzaro JM, Labar D, Sperling MR, Sharan A, Sandok E, Handforth A, Stern JM, Chung S, Henderson JM, French J, Baltuch G, Rosenfeld WE, Garcia P, Barbaro NM, Fountain NB, Elias WJ, Goodman RR, Pollard JR, Tröster AI, Irwin CP, Lambrecht K, Graves N, Fisher R; SANTE Study Group.

Neurology. 2015 Mar 10;84(10):1017-25. doi: 10.1212/WNL.0000000000001334. Epub 2015 Feb 6.

6.

Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor.

Handforth A.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: 02-92-769-1. doi: 10.7916/D8TD9W2P. Epub 2012 Sep 12.

7.

Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor.

Nahab FB, Handforth A, Brown T, Shin C, Quesada A, Dong C, Haubenberger D, Hallett M.

Neurotherapeutics. 2012 Jul;9(3):635-8. doi: 10.1007/s13311-012-0121-1.

8.

C-terminal mechano-growth factor induces heme oxygenase-1-mediated neuroprotection of SH-SY5Y cells via the protein kinase Cϵ/Nrf2 pathway.

Quesada A, Ogi J, Schultz J, Handforth A.

J Neurosci Res. 2011 Mar;89(3):394-405. doi: 10.1002/jnr.22543. Epub 2011 Jan 13. Erratum in: J Neurosci Res. 2011 Jul;89(7):1142.

PMID:
21259326
9.

Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor.

Quesada A, Bui PH, Homanics GE, Hankinson O, Handforth A.

Eur J Pharmacol. 2011 May 20;659(1):30-6. doi: 10.1016/j.ejphar.2011.01.004. Epub 2011 Jan 21.

10.

A pilot efficacy and tolerability trial of memantine for essential tremor.

Handforth A, Bordelon Y, Frucht SJ, Quesada A.

Clin Neuropharmacol. 2010 Sep-Oct;33(5):223-6. doi: 10.1097/WNF.0b013e3181ebd109.

PMID:
20838216
11.

T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.

Handforth A, Homanics GE, Covey DF, Krishnan K, Lee JY, Sakimura K, Martin FC, Quesada A.

Neuropharmacology. 2010 Nov;59(6):380-7. doi: 10.1016/j.neuropharm.2010.05.012. Epub 2010 Jun 12.

12.

Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy.

Fisher R, Salanova V, Witt T, Worth R, Henry T, Gross R, Oommen K, Osorio I, Nazzaro J, Labar D, Kaplitt M, Sperling M, Sandok E, Neal J, Handforth A, Stern J, DeSalles A, Chung S, Shetter A, Bergen D, Bakay R, Henderson J, French J, Baltuch G, Rosenfeld W, Youkilis A, Marks W, Garcia P, Barbaro N, Fountain N, Bazil C, Goodman R, McKhann G, Babu Krishnamurthy K, Papavassiliou S, Epstein C, Pollard J, Tonder L, Grebin J, Coffey R, Graves N; SANTE Study Group.

Epilepsia. 2010 May;51(5):899-908. doi: 10.1111/j.1528-1167.2010.02536.x. Epub 2010 Mar 17.

13.

C-terminal mechano growth factor protects dopamine neurons: a novel peptide that induces heme oxygenase-1.

Quesada A, Micevych P, Handforth A.

Exp Neurol. 2009 Dec;220(2):255-66. doi: 10.1016/j.expneurol.2009.08.029. Epub 2009 Sep 6.

PMID:
19735655
14.

Zonisamide for essential tremor: an evaluator-blinded study.

Handforth A, Martin FC, Kang GA, Vanek Z.

Mov Disord. 2009 Feb 15;24(3):437-40. doi: 10.1002/mds.22418.

PMID:
19117357
15.

The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil.

Bui PH, Quesada A, Handforth A, Hankinson O.

Drug Metab Dispos. 2008 Jul;36(7):1291-9. doi: 10.1124/dmd.107.020115. Epub 2008 Apr 14.

16.

Deep brain stimulation of the subthalamic nucleus as adjunct treatment for refractory epilepsy.

Handforth A, DeSalles AA, Krahl SE.

Epilepsia. 2006 Jul;47(7):1239-41.

17.

Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.

Martin FC, Handforth A.

Mov Disord. 2006 Oct;21(10):1641-9.

PMID:
16773639
18.
19.
20.

Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications.

Martin FC, Thu Le A, Handforth A.

Mov Disord. 2005 Mar;20(3):298-305.

PMID:
15580562
21.
22.

Vagus nerve stimulation inhibits harmaline-induced tremor.

Krahl SE, Martin FC, Handforth A.

Brain Res. 2004 Jun 11;1011(1):135-8.

PMID:
15140653
23.

Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial.

Handforth A, Ondo WG, Tatter S, Mathern GW, Simpson RK Jr, Walker F, Sutton JP, Hubble JP, Jankovic J.

Neurology. 2003 Nov 25;61(10):1401-5.

PMID:
14638963
24.

Right-sided vagus nerve stimulation reduces generalized seizure severity in rats as effectively as left-sided.

Krahl SE, Senanayake SS, Handforth A.

Epilepsy Res. 2003 Sep;56(1):1-4.

PMID:
14529948
25.

Vagus nerve stimulation: analysis of device parameters in 154 patients during the long-term XE5 study.

DeGiorgio CM, Thompson J, Lewis P, Arrambide S, Naritoku D, Handforth A, Labar D, Mullin P, Heck C; VNS U.S. Study Group.

Epilepsia. 2001 Aug;42(8):1017-20.

26.
27.

Suppression of harmaline-induced tremor in rats by vagus nerve stimulation.

Handforth A, Krahl SE.

Mov Disord. 2001 Jan;16(1):84-8.

PMID:
11215598
28.

Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures.

DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B, Reed R, Collins S, Tecoma E, Morris GL, Vaughn B, Naritoku DK, Henry T, Labar D, Gilmartin R, Labiner D, Osorio I, Ristanovic R, Jones J, Murphy J, Ney G, Wheless J, Lewis P, Heck C.

Epilepsia. 2000 Sep;41(9):1195-200.

29.

Seizure suppression by systemic epinephrine is mediated by the vagus nerve.

Krahl SE, Senanayake SS, Handforth A.

Epilepsy Res. 2000 Feb;38(2-3):171-5.

PMID:
10642045
30.
31.

Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome.

DeLorey TM, Handforth A, Anagnostaras SG, Homanics GE, Minassian BA, Asatourian A, Fanselow MS, Delgado-Escueta A, Ellison GD, Olsen RW.

J Neurosci. 1998 Oct 15;18(20):8505-14.

32.

A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group.

Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE, Mamdani MB.

N Engl J Med. 1998 Sep 17;339(12):792-8.

33.

Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial.

Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL 3rd, Salinsky MC, Osorio I, Ristanovic RK, Labiner DM, Jones JC, Murphy JV, Ney GC, Wheless JW.

Neurology. 1998 Jul;51(1):48-55.

PMID:
9674777
34.

Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior.

Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL, Krasowski MD, Rick CE, Korpi ER, Mäkelä R, Brilliant MH, Hagiwara N, Ferguson C, Snyder K, Olsen RW.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4143-8.

35.
36.
37.

Rising dose study of safety and tolerance of flunarizine.

Handforth A, Mai T, Treiman DM.

Eur J Clin Pharmacol. 1995;49(1-2):91-4.

PMID:
8751028
38.

Mapping of limbic seizure progressions utilizing the electrogenic status epilepticus model and the 14C-2-deoxyglucose method.

Handforth A, Ackermann RF.

Brain Res Brain Res Rev. 1995 Jan;20(1):1-23. Review.

PMID:
7711764
39.

Efficacy and tolerance of long-term, high-dose gabapentin: additional observations.

Handforth A, Treiman DM.

Epilepsia. 1994 Sep-Oct;35(5):1032-7.

PMID:
7925148
41.

Dezinamide for partial seizures: results of an n-of-1 design trial.

Privitera MD, Treiman DM, Pledger GW, Sahlroot JT, Handforth A, Linde MS, France CR, Cereghino JJ, McCutchen CB, Wood JH.

Neurology. 1994 Aug;44(8):1453-8.

PMID:
8058148
42.
43.

Interictal spiking increases 2-deoxy[14C]glucose uptake and c-fos-like reactivity.

Handforth A, Finch DM, Peters R, Tan AM, Treiman DM.

Ann Neurol. 1994 Jun;35(6):724-31.

PMID:
8210230
44.
45.

Electrogenic status epilepticus induced from numerous limbic sites.

Handforth A, Ackermann RF.

Epilepsy Res. 1993 May;15(1):21-6.

PMID:
8325275
47.
48.

Implications of stimulus factors governing kindled seizure threshold.

Handforth A.

Exp Neurol. 1984 Oct;86(1):33-9.

PMID:
6479279
49.
50.

Paraneoplastic subacute necrotic myelopathy.

Handforth A, Nag S, Sharp D, Robertson DM.

Can J Neurol Sci. 1983 Aug;10(3):204-7.

PMID:
6616351

Supplemental Content

Loading ...
Support Center